Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma

Journal of Hepatology

Volumn 31, Issue 2, 1999, Pages 323-331

  Ninomiya, Tsuneyuki ^a   Akbar, Sk Md Fazle ^a   Masumoto, Toshikazu ^a   Horiike, Norio ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dysfunction of dendritic cells; Hepatocellular carcinoma; Immature phenotype

Indexed keywords

CYTOKINE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; PHENOTYPE; PRIORITY JOURNAL;

EID: 0032807075     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80231-1     Document Type: Article

References (29)

1. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol. 17:1995;261-281.
2. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 188:1998;341-350.
3. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:1997;3245-3287.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
5. Hermans IF, Daish A, Yang J, Ritchie DS, Ronchese F. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res. 58:1998;3909-3917.
6. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol. 170:1996;101-110.
7. Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, et al. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer. 78:1998;196-201.
8. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 2:1996;52-58.
9. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer. 73:1997;309-316.
10. Thurnher M, Radmayr C, Ramoner R, Ebner S, Bock G, Klocker H, et al. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer. 68:1996;1-7.
11. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1996;1096-1103.
12. Alexandroff AB, Robins RA, Murray A, James K. Tumour immunology: false hopes - new horizons? Immunol Today. 19:1998;247-250.
13. Grabbe S, Beissert S, Schwarz T, Granstein RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today. 16:1995;117-121.
14. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic cells and carcinoma cells. Nat Med. 3:1997;558-561.
15. Fields RC, Shimizu K, Mulle JJ. Murine dendritic cells pulsed with tumor lysates mediate antitumor immune responses in vitro and in vivo. Proc Natl Aca Sci USA. 95:1998;9482-9487.
16. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic cells and carcinoma cells. Proc Natl Acad Sci USA. 95:1998;6279-6283.
17. Chen B-G, Shi Y, Smith JD, Choi D, Geiger JD, Mule JJ. The role of tumor necrosis factor a in modulating the quantity of peripheral blood-derived, cytokin-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigen. Blood. 91:1998;4652-4660.
18. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 182:1995;389-400.
19. Bonham CA, Lu L, Li Y, Hoffman RA, Simmons RL, Thomson AW. Nitric oxide production by mouse bone marrow-derived dendritic cells: implications for the regulation of allogeneic T cell responses. Transplantation. 62:1996;1871-1877.
20. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 180:1994;83-93.
21. Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, et al. Generation tumor immunity by bone marrow-derived dendritic cells correlates with the dendritic cell maturation stage. J Immunol. 162:1999;168-175.
22. Steinbrink K, Wolfl M, Jounleit H, Knop J, Enk AH. Induction of tolerance by IL-10 treated dendritic cells. J Immunol. 159:1997;4772-4780.
23. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumorimmunity against central nervous system tumors. J Exp Med. 186:1997;1177-1182.
24. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 4:1998;594-600.
25. Harada M, Tamada K, Abe K, Yasumoto K, Kimura G, Nomoto K. Role of the endogenous production of interleukin 12 in immunotherapy. Cancer Res. 58:1998;3073-3077.
26. Stefanini GF, Mazzetti M, Zamorano MA, Capelli S, Castelli E, Degli Esposti P, et al. Circulating LAK-1 cells and autologous mixed lymphocyte reaction in patients with hepatocellular carcinoma. Am J Gastroenterol. 84:1989;396-399.
27. Kakumu S, Okumura A, Ishikawa T, Iwata K, Yano M, Yoshioka K. Production of interleukins 10 and 12 by peripheral blood mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection. Clin Exp Immunol. 108:1997;138-143.
28. Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer. 70:1992;709-713.
29. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 179:1994;1109-1118.